Frontier Biotechnologies Inc
688221
Company Profile
Business description
Frontier Biotechnologies Inc is an innovative biomedical company. It is engaged in the production and sales of innovative drugs for major unmet clinical needs. The company focuses on the research and development of new drugs in the field of long-acting peptides and differentiated product development strategies for unmet clinical and patient needs.
Contact
No. 5 Gande Road
7th Floor, Science Park
Jiangning District, Jiangsu Province
Nanjing211122
CHNT: +86 2569648375
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
302
Stocks News & Analysis
stocks
Fair value upgrade for this ASX income player
Headwinds in listed energy stocks likely to have passed
stocks
The SpaceX IPO and the Elon Musk factor
Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,747.40 | 75.00 | 0.86% |
| CAC 40 | 7,772.45 | 70.50 | 0.92% |
| DAX 40 | 22,562.88 | 262.13 | 1.18% |
| Dow JONES (US) | 45,216.14 | 49.50 | 0.11% |
| FTSE 100 | 10,127.96 | 160.61 | 1.61% |
| HKSE | 24,657.41 | 93.38 | -0.38% |
| NASDAQ | 20,794.64 | 153.72 | -0.73% |
| Nikkei 225 | 51,820.30 | 65.55 | -0.13% |
| NZX 50 Index | 12,866.42 | 117.50 | 0.92% |
| S&P 500 | 6,343.72 | 25.13 | -0.39% |
| S&P/ASX 200 | 8,546.50 | 69.30 | 0.82% |
| SSE Composite Index | 3,910.01 | 13.27 | -0.34% |